{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:27:31Z","timestamp":1793298451248,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jtho.2026.103564","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:28:30Z","timestamp":1769819310000},"page":"103564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial"],"prefix":"10.1016","volume":"21","author":[{"given":"Silvia","family":"Novello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Lotte","family":"Buchmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Wen-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thi Thai","family":"Hoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed M.S.","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Olivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103564_bib1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2026.103564_bib2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib4","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/theoncologist.2009-0026","article-title":"New advances in the second-line treatment of small cell lung cancer","volume":"14","author":"Hurwitz","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2026.103564_bib6","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/curroncol28040243","article-title":"Patterns of relapse in small cell lung cancer: competing risks of thoracic versus CNS relapse","volume":"28","author":"Ellis","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib7","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ijrobp.2024.02.063","article-title":"Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: a brief report from the CONVERT trial","volume":"119","author":"Walls","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2026.103564_bib8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103564_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.103564_bib10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2026.103564_bib11","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103564_bib12","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103564_bib13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib14","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103564_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.jtho.2026.103564_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fphar.2017.00339","article-title":"The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature","volume":"8","author":"Bennett","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtho.2026.103564_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001021","article-title":"Lung cancer symptoms at diagnosis: results of a nationwide registry study","volume":"5","author":"Ruano-Ravi\u00f1a","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.103564_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lungcan.2022.02.002","article-title":"Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer","volume":"166","author":"Killingberg","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103564_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2026.103564_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2026.103564_bib23","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S1556-0864(18)30355-1","article-title":"80P Understanding the patient perspective of small cell lung cancer (SCLC)","volume":"13","author":"Ryd\u00e9n","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.03.039","article-title":"Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: validation study","volume":"170","author":"Machingura","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2026.103564_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib27","author":"Scott"},{"key":"10.1016\/j.jtho.2026.103564_bib28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute Workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jtho.2026.103564_bib29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdq576","article-title":"Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)","volume":"22","author":"Le P\u00e9choux","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35663","article-title":"Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance","volume":"131","author":"Ganti","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2026.103564_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2020.09.003","article-title":"Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study","volume":"149","author":"Goldman","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103564_bib32","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.103564_bib33","article-title":"Patient-reported health-related quality of life in KEYNOTE-604: pembrolizumab or placebo added to etoposide and platinum as first-line therapy for extensive-stage SCLC","volume":"4","author":"Kim","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.103564_bib34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2017.09.011","article-title":"Patient-reported outcome measures (PROMs) in the management of lung cancer: a systematic review","volume":"113","author":"Bouazza","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103564_bib35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11912-023-01462-w","article-title":"Immune-related adverse events in patients with lung cancer","volume":"25","author":"Sacchi de Camargo Correia","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtho.2026.103564_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2026.103964","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000}},{"DOI":"10.1016\/j.jtho.2026.103964","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:32:30Z","timestamp":1787171550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1556086426000171"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103564","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103564"}}